JP2013523843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523843A5 JP2013523843A5 JP2013504061A JP2013504061A JP2013523843A5 JP 2013523843 A5 JP2013523843 A5 JP 2013523843A5 JP 2013504061 A JP2013504061 A JP 2013504061A JP 2013504061 A JP2013504061 A JP 2013504061A JP 2013523843 A5 JP2013523843 A5 JP 2013523843A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- cancer
- antibody
- drug according
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32460810P | 2010-04-15 | 2010-04-15 | |
| US61/324,608 | 2010-04-15 | ||
| PCT/AU2011/000386 WO2011127519A1 (en) | 2010-04-15 | 2011-04-05 | Combination treatment with vegf-c antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015185027A Division JP2016040269A (ja) | 2010-04-15 | 2015-09-18 | Ｖｅｇｆ−ｃ拮抗剤を用いた併用治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013523843A JP2013523843A (ja) | 2013-06-17 |
| JP2013523843A5 true JP2013523843A5 (enExample) | 2014-05-22 |
Family
ID=44798165
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013504061A Pending JP2013523843A (ja) | 2010-04-15 | 2011-04-05 | Ｖｅｇｆ−ｃ拮抗剤を用いた併用治療 |
| JP2015185027A Withdrawn JP2016040269A (ja) | 2010-04-15 | 2015-09-18 | Ｖｅｇｆ−ｃ拮抗剤を用いた併用治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015185027A Withdrawn JP2016040269A (ja) | 2010-04-15 | 2015-09-18 | Ｖｅｇｆ−ｃ拮抗剤を用いた併用治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20120207671A1 (enExample) |
| EP (1) | EP2558122A4 (enExample) |
| JP (2) | JP2013523843A (enExample) |
| CA (1) | CA2796205A1 (enExample) |
| WO (1) | WO2011127519A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2863188A1 (en) * | 2012-02-02 | 2013-08-08 | Acceleron Pharma Inc. | Alk1 antagonists and their uses in treating renal cell carcinoma |
| US20140057851A1 (en) * | 2012-08-24 | 2014-02-27 | WKD Holding Oy | Anti-Angiogenic Gene Therapy With Soluble VEGF Receptors -1, -2 and -3 Together With Paclitaxel Prolongs Survival Of Mice With Human Ovarian Carcinoma |
| US12024568B2 (en) | 2012-09-13 | 2024-07-02 | Cornell University | Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies |
| US10561707B2 (en) | 2013-09-08 | 2020-02-18 | Technion Research And Development Foundation Ltd. | Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases |
| KR102131370B1 (ko) | 2013-10-18 | 2020-07-08 | 삼성전자주식회사 | Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도 |
| KR102700777B1 (ko) * | 2015-09-17 | 2024-08-29 | 이뮤노젠 아이엔씨 | 항-folr1 면역접합체를 포함하는 치료제 조합 |
| EP3407846B1 (en) * | 2016-01-25 | 2021-09-22 | Technion Research & Development Foundation Limited | Composition comprising a semaphorin 3c or variant thereof for use in treating age-related macular degeneration |
| EP3272771A1 (en) * | 2016-07-22 | 2018-01-24 | Centre National De La Recherche Scientifique | Treatment for use for preventing metastasis in a subject exposed to cancer treatment inducing p38 activation |
| EP3446704A1 (en) | 2017-08-24 | 2019-02-27 | Isofol Medical AB | [6r]-mthf - an efficient folate alternative in 5-fluorouracil based chemotherapy |
| EP3582812A1 (en) | 2017-02-14 | 2019-12-25 | Isofol Medical AB | METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION |
| WO2018189403A1 (en) | 2017-04-14 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancer |
| WO2022238459A1 (en) * | 2021-05-11 | 2022-11-17 | Centre National De La Recherche Scientifique (Cnrs) | New humanized anti-vegfc antibodies and uses thereof |
| AU2022327397A1 (en) * | 2021-08-13 | 2024-03-14 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-vegf a and -vegf c bispecific antibody and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6824777B1 (en) * | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| US20050232921A1 (en) * | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
| WO2002083704A1 (en) * | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
| HUE058817T2 (hu) * | 2004-09-03 | 2022-09-28 | Genentech Inc | Humanizált anti-béta7 antagonisták és alkalmazásaik |
| MX2009004436A (es) * | 2006-10-27 | 2009-05-22 | Janssen Pharmaceutica Nv | Derivados de quinazolina macrociclicos como inhibidores del factor de crecimiento endotelial vascular r3. |
| US20100029491A1 (en) * | 2008-07-11 | 2010-02-04 | Maike Schmidt | Methods and compositions for diagnostic use for tumor treatment |
| WO2011106697A1 (en) * | 2010-02-25 | 2011-09-01 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
-
2011
- 2011-04-05 JP JP2013504061A patent/JP2013523843A/ja active Pending
- 2011-04-05 WO PCT/AU2011/000386 patent/WO2011127519A1/en not_active Ceased
- 2011-04-05 EP EP11768266.6A patent/EP2558122A4/en not_active Withdrawn
- 2011-04-05 CA CA2796205A patent/CA2796205A1/en not_active Abandoned
- 2011-04-05 US US13/501,600 patent/US20120207671A1/en not_active Abandoned
-
2013
- 2013-08-29 US US14/013,203 patent/US20130344065A1/en not_active Abandoned
-
2015
- 2015-04-27 US US14/697,175 patent/US20150224191A1/en not_active Abandoned
- 2015-09-18 JP JP2015185027A patent/JP2016040269A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523843A5 (enExample) | ||
| Fornaro et al. | FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO) | |
| Walker et al. | Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? | |
| Watters et al. | Oral complications of targeted cancer therapies: a narrative literature review | |
| Guo et al. | Interleukin-6 signaling pathway in targeted therapy for cancer | |
| JP2018508512A5 (enExample) | ||
| JP2008531576A5 (enExample) | ||
| RU2020102237A (ru) | Связывающие il-1-бета антитела для применения в лечении рака | |
| JP2011512332A5 (enExample) | ||
| JP2007526455A5 (enExample) | ||
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| JP2017533912A5 (enExample) | ||
| JP2017506264A5 (enExample) | ||
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| IL276434B1 (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| JP2016520528A5 (enExample) | ||
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2015532292A5 (enExample) | ||
| JP2018516911A5 (enExample) | ||
| JP2014034576A5 (enExample) | ||
| ME02148B (me) | Notch-vezivni agensi i antagonisti i postupci za njihovo korišćenje | |
| MX2020006042A (es) | Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas. | |
| RU2018111529A (ru) | Комбинированная терапия для лечения рака | |
| JP2013520442A5 (enExample) | ||
| RU2015143437A (ru) | Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака |